Aequus Biopharma Inc.

The Genetic Polymer technology around which Aequus Biopharma, a spin-out of Cell Therapeutics, is being formed will allow it to develop long-acting versions of G-CSF, EPO, and other therapeutic proteins. The founders believe these novel molecules will offer more convenient dosing, and not infringe on the patents already covering the therapeutic use of the proteins.